The DBCG RT Natural Trial
Partial Breast Versus no Irradiation for Women >=60 Years Operated With Breast Conservation for an Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial.
- Project leaders: Vidar Flote and Kristin Reinertsen
AXSANA
AXillary Surgery after NeoAdjuvant treatment.
- Project leader: Ellen Schlichting
SERENA-4
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.
- Project leader: Anna Sætersdal
DESTINYBreast12
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer.
- Project leader: Olav Engebråten
NAPEER+
NeoAdjuvant Personalized therapy in Estrogen Receptor positive (+) breast cancer.
- Project leader: Olav Engebråten
Improved breast cancer therapy
Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
- Project leader: Olav Engebråten
The Prospective Study
Late effects after treatment for breast cancer and lymphoma.
- Project leaders: Cecilie Kiserud and Kristin Reinertsen
POSITIVE
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive cancer who desire pregnancy.
- Project leader: Anna Sætersdal
ALICE
A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
- Project leader: Jon Amund Kyte
ICON
A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer.
- Project leader: Jon Amund Kyte
EMIT1
Establishment of Molecular profiling for Individual clinical routine Treatment decision in Early Breast Cancer.
- Project leader: Bjørn Naume
OPTIMA/EMIT2
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis.
- Project leader: Bjørn Naume
SERENA-6
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitors (Palbociclib or Abemaciclib) vs Continuing NSAI + CDK4/6 Inhibitors in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Clinical or Radiological Progression During 1L Treatment with NSAI + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study.
- Project leader: Trygve Lofterød
TAORMINA
Treatment of Oligometastatic breast cancer – a randomized phase-3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1. line treatment.
- Project leader: Vidar Flote